Genmab A/S announced that Johnson & Johnson (J&J) has decided not to exercise its option for a worldwide license to develop, manufacture, and commercialize HexaBody-CD38 (GEN3014). Following this decision, Genmab will not pursue further clinical development of HexaBody-CD38.
While initial clinical data for HexaBody-CD38 showed promising robust clinical efficacy, Genmab's decision to discontinue development was based on a thorough evaluation of the data, the market landscape, and its portfolio prioritization. Preliminary Phase 2 data showed an overall response rate (ORR) of 55% for HexaBody-CD38 IV versus 52% for daratumumab SC in anti-CD38 antibody-naïve relapsed or refractory multiple myeloma patients.
Genmab stated that this news does not impact its 2025 financial guidance. The company will maintain its focus and disciplined investments in its promising late-stage proprietary clinical pipeline, including EPKINLY, rinatabart sesutecan (Rina-S), and acasunlimab.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.